Apyx Medical Corp APYX.OQ APYX.O is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The Clearwater Florida-based company is expected to report a 4.5% increase in revenue to $12.002 million from $11.49 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Apyx Medical Corp is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Apyx Medical Corp is $4.00, about 20% above its last closing price of $3.20
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.09 | -0.09 | -0.09 | Met | 3.6 |
Mar. 31 2025 | -0.12 | -0.12 | -0.10 | Beat | 16.7 |
Dec. 31 2024 | -0.17 | -0.16 | -0.12 | Beat | 25 |
Sep. 30 2024 | -0.19 | -0.19 | -0.14 | Beat | 24.6 |
Jun. 30 2024 | -0.20 | -0.20 | -0.19 | Beat | 4.1 |
Mar. 31 2024 | -0.22 | -0.21 | -0.22 | Missed | -2.6 |
Dec. 31 2023 | -0.20 | -0.18 | -0.28 | Missed | -57.7 |
Sep. 30 2023 | -0.12 | -0.11 | -0.13 | Missed | -14.8 |
This summary was machine generated November 4 at 14:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)